Shortening the ex vivo culture of CD19‐specific CAR T‐cells retains potent efficacy against acute lymphoblastic leukemia without CAR T‐cell‐related encephalopathy syndrome or severe cytokine release syndrome. Issue 12 (2nd October 2019) - Tu, Sanfang